The combination of the lipophilic antifolate trimetrexate and the rescue agent leucovorin has shown promise in the treatment ofPneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. The pharmacokinetic behavior of trimetrexate administered either by intravenous bolus or oraly was studied in six patients with acquired immunodeficiency syndrome with a reversed-phase high-pressure liquid chromotography assay. The mean clearance following bolus injection was 38 m/min per m2, with a range of 15 to 55 ml/min per mi2. The postdistributive half-life ranged from 6 to 16 h. With oral administration, the mean bioavailability was 44% (range, 19 to 67%). An oral dose of 60 mg/M2 (162 Lnmol/m2) resulted in concentrations in plasma that approximated those achieved with a 30-mg/M2 (81-ILmol/m2) intravenous dose. The toxicity of this combination regimen was minimal. It appears that the oral route is a practical route of administration for trimetrexate in patients with acquired immunodeficiency syndrome requiring long-term outpatient treatment or prophylaxis for P. carinii pneumonia.
Pneumocystis carinii pneumonia is the most common opportunistic infection in patients with acquired immunodeficiency syndrome (AIDS). The attack rate is at least 65% in this patient population, and this infection accounts for 25% of all deaths (6, 14) . Conventional therapy with the combination of trimethoprim and sulfamethoxazole or pentamidine isethionate is associated with a 20 to 40% failure rate and a 60 to 100% incidence of adverse reactions (12) . For these reasons new antiprotozoal drugs are being evaluated.
A novel approach that has shown promise for the treatment ofP. carinii pneumonia in patients with AIDS is the use of a regimen combining trimetrexate (2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline [TMTX] ) and leucovorin (5-formyl-tetrahydrofolate) (1) . TMTX is a lipid soluble antifolate that readily crosses both mammalian and protozoan cell membranes independently of the folate membrane transport system (7, 11) . Like methotrexate, the classical folate antagonist, TMTX is a potent inhibitor of the enzyme dihydrofolate reductase, which converts dihydrofolate to the active, chemically reduced tetrahydrofolate form (5) . Recent studies have shown TMTX to be a much more potent inhibitor of protozoal dihydrofolate reductase than the conventionally used antifolates trimethoprim and pyrimethamine. Leucovorin, which is transported across the mammalian cell membrane by a specific transport system that is not present in the pneumocystis cell wall, can selectively rescue host cells from the toxic effects of TMTX.
The pharmacokinetics of TMTX administered by intravenous (i.v.) bolus has been described in the initial phase I trials performed in cancer patients refractory to conventional treatment (3, 10, 13) . The drug is cleared primarily by biotransformation and has a postdistributive half-life of 12 to 24 h (3, 13) . However, the bioavailability of TMTX following oral administration in humans has not been reported. The oral route is clearly more convenient for the treatment or * Corresponding author.
prophylaxis of protozoal disease in patients with AIDS. In this report we present results of a pharmacokinetic study of TMTX in patients with AIDS who received the drug by both the i.v. and oral routes.
MATERIALS AND METHODS
Drug formulation and adminiistration. TMTX was supplied by the Investigational Drug Branch of the National Cancer Institute as a sterile lyophilized powder in 6-ml vials containing 50 mg of the drug as the glucuronate salt. The drug was reconstituted with 1.9 ml of sterile water (25 mg/ml) and injected by i.v. bolus. Because of its insolubility in chloridecontaining solutions, TMTX could be injected only into i.v. lines containing 5% glucose in water. The i.v. preparation, mixed in the same fashion, was also used for oral administration.
Patients. Six patients with AIDS (ages 27 to 45 years) who were being treated for P. carinii pneumonia (four patients) or toxoplasmosis (two patients) with daily i.v. TMTX (30 mg/M2 or 81 [umolIm2) administered as a bolus injection and leucovorin (20 mg/M2 every 6 h, i.v. or peroral) by an approved National Cancer Institute protocol participated in this study. Further details of the drug doses and schedules and the results of the trial have been reported separately (1) . None of these patients were receiving sulfamethoxazole at the time of study. Liver function and renal function were assessed in all patients prior to pharmacokinetic studies and found to be within the normal range. Informed consent was obtained from all patients prior to participation in this study.
All patients had completed at least 3 weeks of treatment with i.v. TMTX and leucovorin. Prior to discontinuation of i.v. TMTX, a dose was monitored by drawing heparinized blood samples prior to the dose and at 5 and 30 min and 1, 2, 4, 6, 8, and 24 h after the dose. Plasma was separated by sedimentation and stored frozen until assayed. In the patients with P. carinii pneumonia, oral TMTX (60 mg/M2 or BIOAVAILABILITY OF ORAL TRIMETREXATE IN AIDS PATIENTS (15) . The bioavailability of the oral dose (F) was was calculated from the following equation (8) (Fig. 1) .
In these six patients, the only side effect of the oral TMTX and leucovorin was the bitter taste of the TMTX solution.
DISCUSSION
The bioavailability of oral TMTX in patients with AIDS who were infected with either P. carinii or toxoplasmosis was 44%. With a single daily oral dose of 60 mg/m2 (162 LmolI/m2, which was twice the effective intravenous dose), concentrations in plasma approximated those achieved with the i.v. dose and were maintained above or near 1 ,umol/liter, a concentration that inhibited P. carinii in vitro for 24 h. However, the variability in the rate of drug clearance noted in this study and previous pharmacokinetic studies with cancer patients suggests that adjustments in the dosing schedule based on therapeutic drug monitoring may be required in patients with either very rapid or delayed clearance. The incomplete bioavailability of this drug may be due either to incomplete absorption or to presystemic metabolism of the drug. Although no data were generated in this study to define the mechanism of the limited bioavailability, in previous pharmacokinetic studies in monkeys, higher circulating concentrations of dihydrofolate reductase-inhibiting metabolites of TMTX were detected after oral administration than after i.v. administration, suggesting some presystemic metabolism of the drug (2) .
The oral absorption of the classical antifolate methotrexate has been well studied and appears to be a saturable, carrier-dependent process. As the dose of methotrexate is increased, the absorption becomes prolonged and incomplete (4, 9) . Further studies with rat jejunum have demonstrated that methotrexate shares a carrier-mediated transport system with the naturally occuring folates (16) . It is unlikely that TMTX is dependent on this carrier for absorption, since cellular uptake is independent of the folate carrier. Up to 60% of a 60-mg/M2 (162-,umol/m2) dose of TMTX is absorbed, in contrast to the small fraction of a comparable 80-mg/M2 (176-11mol/m2) dose of methotrexate that reaches the systemic circulation (9) .
The primary toxicities of TMTX in patients with refractory cancer who did not receive concurrent leucovorin include myelosuppression, mucositis, a maculopapular rash, and elevations in hepatic transaminases (3, 13) . On a daily schedule for 5 days, the tolerable dose in this patient population is 8 mg/M2 (22 1umol/m2), well below the 30-mg/M2
(81-_,mol/m2) dose administered daily and indefinitely with leucovorin in patients with AIDS who experience minimal toxicity. Thus it appears that leucovorin decreases the frequency of adverse reactions.
In conclusion, it appears that the oral route will be practical for patients with P. carinii pneumonia who can be managed as outpatients or for patients who require long-term prophylaxis. Further trials to evaluate the efficacy of an oral regimen of TMTX and leucovorin in these situations are needed. General use must also await the development of a formulation of the drug specifically for oral administration.
